BioLineRx Enters Co-Development Agreement with GenFleet to Further Develop Motixafortide in PDAC, Advised by MSQ Ventures
PR96787
BioLineRx Enters Co-Development Agreement with GenFleet to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC), Advised by MSQ Ventures
NEW YORK, June 29, 2022 /PRNewswire=KYODO JBN/ --
M.S.Q. Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd.
("BioLineRx") (
) (NASDAQ/TASE: BLRX), has successfully entered into a co-development agreement
with GenFleet Therapeutics, Inc. (
), an immuno-oncology focused biopharmaceutical company based in Shanghai,
China, for the development of Motixafortide in pancreatic ductal adenocarcinoma
("PDAC").
Logo - https://mma.prnewswire.com/media/1849947/MSQ_Ventures_Logo.jpg
Under the terms of the agreement, GenFleet will design and execute a randomized
Phase 2b clinical trial that will enroll approximately 200 first-line
metastatic PDAC patients in China. This randomized controlled study will aim to
evaluate the superiority of Motixafortide in combination with an anti-PD-1 and
chemotherapy compared to chemotherapy alone, the current standard of care.
"This collaboration is based on the highly encouraging results from our Phase
2a COMBAT/KEYNOTE-202 study of Motixafortide in combination with an anti-PD-1
and chemotherapy, which provide strong support for continued development in
this very challenging disease. With its broad solid tumor oncology pipeline and
highly experienced development team, we believe we have found an outstanding
partner in GenFleet to execute a rigorously designed randomized Phase 2b
trial," said Philip Serlin (
), CEO of BioLineRx. "The MSQ team helped to navigate through the complexity of
cross-border transactions and secured this transaction by deploying their deep
knowledge of the global market. We are highly impressed with MSQ's "thinking
outside the box" approach and their expertise in deal structuring and
negotiation."
"The results of the COMBAT/KEYNOTE-202 Phase 2a study demonstrate the benefit
of combining the CXCR4 inhibitor Motixafortide with an anti-PD-1 and
chemotherapy in a second-line setting," said Qiang Lu (
), Chairman of GenFleet. "We believe that this combination could be beneficial
to patients in a first-line setting as well, and we hope to confirm this in a
randomized trial. We are thrilled to be partners with BioLineRx in the
development of this late-stage clinical asset, and look forward to initiating
this important trial as quickly as possible. Throughout this journey, MSQ team
has demonstrated professionalism and dedication in helping both of our teams to
reach the finish line in a timely fashion."
Echo Hindle-Yang (
), CEO of MSQ, reflects on the transaction, "This collaboration demonstrates
another excellent example of global co-development, which leverages each
company's regional expertise to accelerate the development of new treatments.
We are excited to see the alliance between BioLineRx and Genfleet to pursue the
treatment of PDAC, which has proven to be incredibly challenging. I am
impressed by Phil's commitment to developing Motixafortide in PDAC which is
also shared by GenFleet's Dr. Lu. With such a strong commitment from each team,
we believe that patients will benefit from this collaboration. We are honored
to move forward with this cross-border partnership, and help achieve future
success.
About MSQ
M.S.Q. Ventures is a New York-based cross-border advisory firm that bridges the
healthcare industries globally by offering our deep knowledge, strong network,
and local insights into the China market.
info@msqventures.com
SOURCE MSQ Ventures
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
